Table 5.
Comparison of AT1R serum concentration with illness category according to NIH Treatment Guidelines in COVID-19 recovered individuals.
| NIH Illness Category | n | AT1R Serum Concentration in COVID-19 Recovered Group (n = 40) | p | ||||||
|---|---|---|---|---|---|---|---|---|---|
| M | Me | Min | Max | Q1 | Q3 | SD | |||
| 1 | 1 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 | - | 0.21 * |
| 2 | 25 | 3.24 | 2.99 | 1.35 | 6.34 | 2.46 | 3.95 | 1.30 | |
| 3 | 10 | 3.24 | 3.28 | 0.28 | 5.55 | 1.71 | 5.04 | 1.72 | |
| 4 | 4 | 2.75 | 1.11 | 0.35 | 8.43 | 0.62 | 4.88 | 3.81 | |
| 1–2 | 26 | 3.40 | 3.02 | 1.35 | 7.19 | 2.46 | 3.98 | 1.49 | 0.45 ** |
| 3–4 | 14 | 3.10 | 3.01 | 0.28 | 8.43 | 1.33 | 5.04 | 2.33 | |
Abbreviations: NIH, National Institutes of Health; n, number of participants; M, mean; Me, median; Min, minimum value; Max, maximum value; Q1, lower quartile; Q3, upper quartile; SD, standard deviation; AT1R, angiotensin II type 1 receptor; p, level of statistical significance. Notes: * Kruskal–Wallis test; ** Mann–Whitney U test.